[go: up one dir, main page]

MX2019011701A - Composiciones de canabinoide y usos. - Google Patents

Composiciones de canabinoide y usos.

Info

Publication number
MX2019011701A
MX2019011701A MX2019011701A MX2019011701A MX2019011701A MX 2019011701 A MX2019011701 A MX 2019011701A MX 2019011701 A MX2019011701 A MX 2019011701A MX 2019011701 A MX2019011701 A MX 2019011701A MX 2019011701 A MX2019011701 A MX 2019011701A
Authority
MX
Mexico
Prior art keywords
glycol
canabinoid
compositions
composition
monohydric
Prior art date
Application number
MX2019011701A
Other languages
English (en)
Other versions
MX391861B (es
Inventor
Hearn Alex
Gupta Ritika
Bowdrey Moira
Original Assignee
Kind Consumer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kind Consumer Ltd filed Critical Kind Consumer Ltd
Publication of MX2019011701A publication Critical patent/MX2019011701A/es
Publication of MX391861B publication Critical patent/MX391861B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/20—Devices using solid inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/20—Devices without heating means
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F42/00—Simulated smoking devices other than electrically operated; Component parts thereof; Manufacture or testing thereof
    • A24F42/60—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0093—Inhalators mechanically breath-triggered without arming or cocking, e.g. acting directly on the delivery valve
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición inhalable para el uso como un medicamento en el tratamiento de un sujeto en donde la composición comprende uno o más canabinoides o un derivado farmacéuticamente aceptable o sal de los mismos, un propelente, un alcohol monohídrico o polihídrico; y un glicol y/o éter de glicol, caracterizado en que la relación de alcohol monohídrico o polihídrico a glicol o éter de glicol en peso es de 6:1 a 1:1, en donde la composición se administra en la forma de un aerosol que tiene una fracción de partícula fina de 60% o más.
MX2019011701A 2014-02-14 2015-02-13 Composiciones de canabinoide y usos MX391861B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1402678.5A GB2524469A (en) 2014-02-14 2014-02-14 A cannabinoid inhaler and composition therefor
US201461941724P 2014-02-19 2014-02-19
GB1420943.1A GB2525269A (en) 2014-02-14 2014-11-25 Cannabinoid compositions and uses
PCT/GB2015/050418 WO2015121673A1 (en) 2014-02-14 2015-02-13 Cannabinoid compositions and uses

Publications (2)

Publication Number Publication Date
MX2019011701A true MX2019011701A (es) 2020-01-09
MX391861B MX391861B (es) 2025-03-21

Family

ID=50440210

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019011701A MX391861B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos
MX2016010541A MX382192B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016010541A MX382192B (es) 2014-02-14 2015-02-13 Composiciones de canabinoide y usos.

Country Status (10)

Country Link
US (4) US10413521B2 (es)
EP (1) EP3104837A1 (es)
JP (2) JP6391701B2 (es)
AU (1) AU2015216718B2 (es)
CA (2) CA3014697C (es)
GB (2) GB2524469A (es)
IL (1) IL247262B (es)
MX (2) MX391861B (es)
NZ (1) NZ723838A (es)
WO (1) WO2015121673A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
JP6676062B2 (ja) * 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
CN108348704B (zh) * 2015-07-20 2021-08-27 医疗发展国际有限公司 用于可吸入液体的吸入器装置
GB2542389A (en) * 2015-09-17 2017-03-22 Kind Consumer Ltd Simulated cigarette
CN205196999U (zh) * 2015-11-23 2016-05-04 深圳市合元科技有限公司 雾化器及电子烟
WO2018152637A1 (en) * 2017-02-22 2018-08-30 Gene Bernaudo Electronic cigarette mixing agent composition systems
GB201712159D0 (en) * 2017-07-28 2017-09-13 Mexichem Fluor Sa De Cv Pharmaceutical composition
GB2567240B (en) * 2017-10-09 2022-04-06 Senzer Ltd An inhaler particularly a cannabinoid inhaler and a method of assembling such an inhaler
US20200330378A1 (en) * 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
EP3946291A4 (en) * 2019-03-24 2022-12-14 Buzzelet Development And Technologies Ltd CANNABIS INHALATION PRODUCTS AND PROCESS FOR THEIR MANUFACTURE
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
GB2588087A (en) * 2019-09-27 2021-04-21 Senzer Ltd Inhalable cannabinoid compositions and uses
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021074790A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN115413243B (zh) 2019-12-23 2024-08-27 Pax实验室公司 蒸发器料盒
GB2595692B (en) 2020-06-03 2024-10-23 Senzer Ltd A refill for an inhaler particularly a cannabinoid inhaler
US20220015443A1 (en) * 2020-07-15 2022-01-20 Altria Client Services Llc Steady state resistance estimation for overheating protection of a non-nicotine e-vaping device
US11744285B2 (en) 2020-07-15 2023-09-05 Altria Client Services Llc Steady state resistance estimation for overheating protection of a nicotine e-vaping device
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
USD1028336S1 (en) 2021-06-22 2024-05-21 Pax Labs, Inc. Vaporizer cartridge
KR102824241B1 (ko) * 2022-11-01 2025-06-25 주식회사 케이티앤지 흡입기
WO2025149460A1 (en) * 2024-01-08 2025-07-17 Oxford Cannabinoid Technologies Holdings Plc Cannabinoid compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
JP2003535813A (ja) * 1999-08-20 2003-12-02 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 半水性溶媒中にデルタ−９−テトラヒドロカンナビノールを含んでなる吸入のための組成物
US6367471B1 (en) * 1999-11-01 2002-04-09 Sheffield Pharmaceuticals, Inc. Internal vortex mechanism for inhaler device
GB2361869B (en) 2000-03-09 2004-09-22 Pharmasol Ltd Sublingual delivery of cannabis
CA2402020C (en) * 2000-03-09 2006-08-29 Gw Pharma Limited Pharmaceutical compositions
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1515711A1 (en) * 2002-06-22 2005-03-23 Norton Healthcare Limited Pharmaceutical composition
US20070099989A1 (en) * 2005-06-20 2007-05-03 Lou Barbato Dronabinol treatment for migraines
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
ES2441963T3 (es) * 2007-10-05 2014-02-07 Sti Pharmaceuticals Ltd. Composición farmacéutica
GB0823491D0 (en) * 2008-12-23 2009-01-28 Kind Consumer Ltd A simulated cigarette device
EP2461857B1 (en) * 2009-08-07 2019-10-02 Kind Consumer Limited An inhaler
GB201003552D0 (en) 2010-03-03 2010-04-21 Kind Consumer Ltd A simulated cigarette
GB201004861D0 (en) * 2010-03-23 2010-05-05 Kind Consumer Ltd A simulated cigarette
WO2012021291A2 (en) 2010-08-09 2012-02-16 University Of Maryland, Baltimore Methods of treating obstructive lung diseases using bitter tastants
HK1204300A1 (en) * 2012-07-05 2015-11-13 Glaxo Group Limited Inhaler device
CN104780795B (zh) * 2012-08-28 2017-08-25 亲切消费者有限公司 吸入器
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof

Also Published As

Publication number Publication date
IL247262B (en) 2020-07-30
US20200147035A1 (en) 2020-05-14
GB2524469A (en) 2015-09-30
WO2015121673A1 (en) 2015-08-20
GB201402678D0 (en) 2014-04-02
MX382192B (es) 2025-03-13
US20200163932A1 (en) 2020-05-28
JP2017506639A (ja) 2017-03-09
NZ723838A (en) 2019-08-30
JP6391701B2 (ja) 2018-09-19
CA3014697A1 (en) 2015-08-20
US10561634B2 (en) 2020-02-18
NZ754337A (en) 2021-10-29
CA2939242C (en) 2018-12-18
MX391861B (es) 2025-03-21
US20190358195A1 (en) 2019-11-28
AU2015216718B2 (en) 2017-11-16
US10413521B2 (en) 2019-09-17
GB2525269A (en) 2015-10-21
JP2018150334A (ja) 2018-09-27
EP3104837A1 (en) 2016-12-21
GB201420943D0 (en) 2015-01-07
AU2015216718A1 (en) 2016-09-01
IL247262A0 (en) 2016-09-29
CA3014697C (en) 2021-05-04
MX2016010541A (es) 2016-11-29
US20170056368A1 (en) 2017-03-02
CA2939242A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX2019011701A (es) Composiciones de canabinoide y usos.
PH12015500686A1 (en) Nicotine composition
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PE20170904A1 (es) Esteroides neuroactivos, composiciones y usos de los mismos
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
ECSP15048122A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
MX395458B (es) Metodos novedosos
MX373711B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
GT201400111A (es) Triazolopiridinas sustituidas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
ECSP14028506A (es) Nucleósidos de espirooxetano de uracilo
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
ECSP18034035A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
SV2015005126A (es) Nuevos compuestos para el tratamiento del cáncer